Seres Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Good afternoon, everybody. Thanks for joining us at the 43rd Annual Canaccord Genuity Growth Conference this afternoon. I'm John Newman. I'm one of the senior biotech analysts here at Canaccord and really excited to have I'm Eric Shaff, the CEO of Seres Therapeutics with us today. So Seres has a very unique therapy for C. difficile and are developing microbiome therapies and other areas. So Eric?
Well, good afternoon, everybody. And thank you, John, and thanks to Canaccord for having us here to present at this year's conference. We think it's a great time to connect with you with the opportunity to talk about Seres, the opportunity to talk about the microbiome, our progress in 2023, and I think as importantly, the future of the microbiome space, and importantly, the future of patients that can be helped with microbiome therapeutics.
We think that in any new modality or medical area, there can be the hope or the promise or even an aspiration
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
